Communiqués Grand Pharmaceutical Group Limited

Actions

512 BMG210A71016

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. 10:08:21 03/09/2026			Varia. 5j.	Varia. 1 janv.
4,880 ^HKD	+0,41%		-7,92%	-37,83%

26/08	Grand Pharmaceutical Group Limited publie ses résultats pour le semestre clos le 30 juin 2026	CI
10/08	Le candidat diagnostic de Grand Pharma contre le cancer obtient le statut "Fast Track" de la FDA ; l'action bondit de 5 %	MT

Communiqués

07/05/25	The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China	AQ
28/06/23	China Monthly Antitrust Update - June 2023	AQ
21/04/23	Telix-Grand Pharma Investor Webcast	AQ
10/05/21	VOLUNTARY ANNOUNCEMENT: SIR-SPHERES Y-90 RESIN MICROSPHERES DOSED THE FIRST HCC PATIENT OF THE U.S. CLINICAL TRIAL	PU
29/04/21	China Grand Pharmaceutical and Healthcare : Proxy form for the annual general meeting to be held on 1 June 2021 or any adjournment thereof	PU
29/04/21	China Grand Pharmaceutical and Healthcare : GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES; RE-ELECTION OF RETIRING DIRECTORS AND APPOINTMENT OF DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING	PU
20/04/21	VOLUNTARY ANNOUNCEMENT: THE GLOBAL INNOVATION PRODUCT OF THE GROUP STC3141 WAS APPROVED TO COMMENCE PHASE IIa CLINICAL RESEARCH IN RELATED TO COVID-19 IN BELGIUM	PU
20/04/21	VOLUNTARY ANNOUNCEMENT: ONCOSEC RECEIVED THE CE MARK CERTIFICATION FROM EU FOR ITS GENE ELECTROTRANSFER DEVICE GENPULSE	PU
19/03/21	China Grand Pharmaceutical and Healthcare : GP (HK) Announces 2020 Annual Results	AQ
08/03/21	VOLUNTARY ANNOUNCEMENT: SIR-SPHERES Y-90 RESIN MICROSPHERES OBTAINED RECOMMENDATION FROM NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE); AND SIRTEX OBTAINED AN APPROVAL FROM FDA TO CONDUCT CLINICAL TRIALS ON PRIMARY LIVER CANCER	PU
04/03/21	China Grand Pharmaceutical and Healthcare : GP (HK)'s First-In-Class Drug STC3141 for Sepsis has been granted A 'Notice of Approval for Clinical Trial of Drugs' issued by the NMPA	AQ
04/03/21	China Grand Pharmaceutical and Healthcare : GP (HK)'s Independently Developed Innovative Glaucoma Treatment Drug Obtained Drug Registration Certificate Breaking Through the Blue Ocean of The Ophthalmic Market Segment	AQ
03/03/21	VOLUNTARY ANNOUNCEMENT: FIRST PATIENT DOSED IN THE PHASE 1B CLINICAL TRIAL FOR SEPSIS OF THE GROUP FIRST-IN-CLASS DRUG STC3141	PU
03/03/21	VOLUNTARY ANNOUNCEMENT: DRUG REGISTRATION CERTIFICATE FOR BIMATOPROST EYE DROPS WAS ISSUED	PU
22/02/21	China Grand Pharmaceutical and Healthcare : GP (HK) Announces Positive Profit Alert the Expected Increase in Consolidated Net Profit Attributable to Owners of the Company for FY2020 No Less Than 40%	AQ
30/11/20	China Grand Pharmaceutical and Healthcare : GP (HK) and eTheRNA Enters into Exclusive Strategic Cooperation and Licensing Agreement on World-class Innovative Products in Greater China	AQ
02/11/20	China Grand Pharmaceutical and Healthcare : Telix Pharmaceuticals and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market	AQ
17/09/20	China Grand Pharmaceutical and Healthcare : INTERIM REPORT 2020	PU
21/08/20	China Grand Pharmaceutical and Healthcare Holdings Limited : - Four Products of GP (HK) that Obtained Consistency Evaluation Approvals, Have Successfully Won the Bids	AQ
18/08/20	China Grand Pharmaceutical and Healthcare : VOLUNTARY ANNOUNCEMENT - SIR-SPHERES Y-90 RESIN MICROSPHERES WAS APPROVED TO FILE NEW DRUG APPLICATION BASED ON CLINICAL RESULTS OBTAINED OVERSEAS	PU
10/08/20	China Grand Pharmaceutical and Healthcare : COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE	PU
10/08/20	China Grand Pharmaceutical and Healthcare : 2020 INTERIM RESULTS ANNOUNCEMENT	PU
02/08/20	China Grand Pharmaceutical and Healthcare : PLACING OF NEW SHARES UNDER GENERAL MANDATE	PU
27/07/20	CONNECTED TRANSACTION: PROPOSED CAPITAL SUBSCRIPTION AND ACQUISITION OF THE EQUITY INTEREST IN THE TARGET COMPANY AND PROPOSED CAPITAL CONTRIBUTION TO THE FUND	PU
17/07/20	China Grand Pharmaceutical and Healthcare : GP (HK) Enters into an Investment Agreement with Revolmmune Introducing the World-Wide Innovative VSV-GPM	AQ